Abstract:N-Phenylpropenoyl-l-amino acids (NPAs) are inducible nitric oxide synthase (iNOS) inhibitors possessing preventive effects for Parkinson's disease (PD). Here, structural modifications for improving the iNOS inhibitory activity and blood–brain barrier (BBB) permeability of NPAs were conducted, leading to 20 optimized NPA derivatives (1–20). Compound 18, with the most potent activity (IC50 = 74 nM), high BBB permeability (Pe = 19.1 × 10–6 cm/s), and high selectivity over other NOS isoforms, was selected as the lead compound. Further studies demonstrated that 18 directly binds to iNOS. In the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced acute PD model, the oral administration of 18 (1 and 2 mg/kg) exerted preventive effects by alleviating the loss of dopaminergic (DAergic) neurons. Notably, in the MPTP-/probenecid-induced chronic PD model, the same dose of 18 also displayed a therapeutic effect by repairing the damaged DAergic neurons. Finally, good pharmacokinetic properties and low toxicity made 18 a promising candidate for the treatment of PD.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00578?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00578</a>.Structure characterization of compounds 1–20 by 1H NMR, 13C NMR, and ESI/HRMS spectroscopy; HPLC analysis of compounds 1–20; chemical structures of 209 designed compounds; docking scores (-kcal/mol) and BBB level prediction of 209 compounds; organ coefficients and blood biochemistry analysis; correlation coefficient R2; H–E staining of main viscera; and effects of 18 on the body weight and hemocyte number (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00578/suppl_file/jm1c00578_si_001.pdf">PDF</a>)Molecular string files for compounds 1–20 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00578/suppl_file/jm1c00578_si_002.csv">CSV</a>)Compound 18 with 1R35 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00578/suppl_file/jm1c00578_si_003.pdb">PDB</a>)This article has not yet been cited by other publications.

Optimization of N-Phenylpropenoyl-l-amino Acids As Potent and Selective Inducible Nitric Oxide Synthase Inhibitors for Parkinson's Disease.

Optimization of N -Phenylpropenoyl- l -amino Acids as Potent and Selective Inducible Nitric Oxide Synthase Inhibitors for Parkinson’s Disease

Identification and Optimization of Nitrophenolic Analogues As Dopamine Metabolic Enzyme Inhibitors for the Treatment of Parkinson’s Disease

An Antisense Oligonucleotide-Loaded Blood–Brain Barrier Penetrable Nanoparticle Mediating Recruitment of Endogenous Neural Stem Cells for the Treatment of Parkinson’s Disease

Design and synthesis of benzo[d]thiazol-2-yl-methyl-4-(substituted)-piperazine-1-carbothioamide as novel neuronal nitric oxide inhibitors and evaluation of their neuroprotecting effect in 6-OHDA-induced unilateral lesioned rat model of Parkinson's disease

Discovery of Novel Benzimidazole Derivatives as Selective and Reversible Monoamine Oxidase B Inhibitors for Parkinson's Disease Treatment

Novel 1-(Prop-2-yn-1-ylamino)-2,3-dihydro-1h-indene-4-thiol Derivatives As Potent Selective Human Monoamine Oxidase B Inhibitors: Design, SAR Development, and Biological Evaluation.

X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson’s Disease

Identification and Optimization of Piperine Analogues As Neuroprotective Agents for the Treatment of Parkinson's Disease Via the Activation of Nrf2/keap1 Pathway.

Iron ions-sequestrable and antioxidative carbon dot-based nano-formulation with nitric oxide release for Parkinson's disease treatment

Identification and optimization of piperine analogues as neuroprotective agents for the treatment of Parkinson’s disease via the activation of Nrf2/keap1 pathway

6-Benzyloxyphthalides as selective and reversible monoamine oxidase B inhibitors with antioxidant and anti-neuroinflammatory activities for Parkinson’s disease treatment

Stimulus-responsive curcumin-based polydopamine nanoparticles for targeting Parkinson?s disease by modulating ?-synuclein aggregation and reactive oxygen species

Brain-Specific Delivery of Dopamine Mediated by N,N-Dimethyl Amino Group for the Treatment of Parkinson’s Disease

A Novel Parkinson's Disease Drug Candidate with Potent Anti-neuroinflammatory Effects through the Src Signaling Pathway

Design, Synthesis, Immunocytochemistry Evaluation, and Molecular Docking Investigation of Several 4-Aminopyridine Derivatives As Potential Neuroprotective Agents for Treating Parkinson'S Disease

Stimulus-responsive curcumin-based polydopamine nanoparticles for targeting Parkinson's disease by modulating α-synuclein aggregation and reactive oxygen species

Neuroprotective Effects and Mechanisms of Action of Multifunctional Agents Targeting Free Radicals, Monoamine Oxidase B and Cholinesterase in Parkinson's Disease Model.

Dl-3-n-Butylphthalide Rescues Dopaminergic Neurons in Parkinson's Disease Models by Inhibiting the NLRP3 Inflammasome and Ameliorating Mitochondrial Impairment

A bibenzyl compound 20C protects rats against 6-OHDA-induced damage by regulating adaptive immunity associated molecules

Investigating the Effect of an Anti-Inflammatory Drug in Determining NURR1 Expression and Thus Exploring the Progression of Parkinson's Disease